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Physiologically based pharmacokinetic (PBPK) models are a means of conducting virtual experiments on a
large scale as an alternative to extensive trials that would be prohibitively time-consuming, unethical, or
otherwise costly. PBPK can be used to compute and test optimal dosing strategies, among other features, of
proposed treatments using known or learned kinetics of the system mimicking complex human physiology. In
turn, PBPK modeling can enable more efficient design and optimization of in vivo experiments, and
consequently accelerate pre-clinical screening and development. I will discuss the application of PBPK
modeling to an important problem in the medical community – the accelerated clearance of PEGylated drugs in
the presence of anti-PEG antibodies (APA). While this phenomenon renders an entire class of drugs (i.e.,
PEGylated drugs) ineffective in many patients, the medical community is largely unaware of how drastically
this can alter prognosis or how to mitigate this effect. I will describe a multi-compartment PBPK model to
accurately capture and ultimately predict clearance behavior, with the goal of validating results against drug
biodistribution data obtained via PET/CT technology. Specifically, I will focus on the initial transient dynamics
as nanomedicines are cleared from the circulation in patients with high APA titers. I will then discuss further
applications for this model in the context of targeted therapeutics.

